302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience

Background

Globally, breast cancer ranks among the primary contributors to the incidence and mortality rates of cancer. Pregnancy-Associated Breast Cancer (PABC) is an infrequent occurrence among young patients (≤45 years), characterized by diagnosis of breast cancer during pregnancy or within a year after delivery. In recent meta-analysis study, PABC patients showed higher mortality than control group. This retrospective case-control study aimed to assess the outcomes of PABC vs non-pregnancy-associated breast cancer (NPABC). The primary outcome measure was overall survival (OS), and secondary outcome measures included disease-free survival (DFS) and recurrence-free survival (RFS).

Methods

A retrospective case-control study was conducted at Shefa El Orman Hospital (SOH) from 2016 to 2021, on patients who met PABC criteria and were under follow-up for at least 3 years. Data collection was carried out using SOH Cancer Registry. 54 PABC patients cross matched with an equal number of control NPABC (≤45 years of age) with a 1:1 ratio. Statistical analysis was conducted through SPSS software. The Chi-square χ2 test was employed to conduct a comparative analysis of frequency distributions for categorical variables.

Results

Total of 54 PABC patients and equal number of control subjects. The median age of PABC cohort = 33 (IQR: 23-42), which did not differ significantly from NPABC (34, IQR: 22-42; p=0.650). PABC demonstrated a higher likelihood of presenting with metastasis at initial diagnosis compared to those NPABC (metastatic: 66.7% vs. 33.3%, p=0.018). PABC patients exhibited a noteworthy contrast in advanced stages during diagnosis, particularly in stage III and IV, in comparison to NPABC patients (61.1% vs 40.7%, p=0.021). Additionally, PABC patients showed an inferior median OS rate (48.9% vs 69.3%, p=0.085) compared to NPABC.

Conclusions

In conclusion, a significant difference exists between the OS and clinicopathological characteristics of PABC patients compared to NPABC. Furthermore, PABC patients exhibited an advanced stage of the disease upon presentation. Larger cohort studies are necessary to evaluate the treatment efficacy and to acquire molecular indicators that may impact the disease outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Shefaa El Orman Oncology Hospital (SOH).

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.